Data di Pubblicazione:
2018
Citazione:
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma / Connors, Joseph M; Jurczak, Wojciech; Straus, David J; Ansell, Stephen M; Kim, Won S; Gallamini, Andrea; Younes, Anas; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Oki, Yasuhiro; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; Chen, Robert; Ramchandren, Radhakrishnan; Zinzani, Pier L; Cunningham, David; Rosta, Andras; Josephson, Neil C; Song, Eric; Sachs, Jessica; Liu, Rachael; Jolin, Hina A; Huebner, Dirk; Radford, John; Luminari, Stefano. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 378:4(2018), pp. 331-344. [10.1056/NEJMoa1708984]
Abstract:
Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.
Tipologia CRIS:
Articolo su rivista
Elenco autori:
Connors, Joseph M; Jurczak, Wojciech; Straus, David J; Ansell, Stephen M; Kim, Won S; Gallamini, Andrea; Younes, Anas; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Oki, Yasuhiro; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; Chen, Robert; Ramchandren, Radhakrishnan; Zinzani, Pier L; Cunningham, David; Rosta, Andras; Josephson, Neil C; Song, Eric; Sachs, Jessica; Liu, Rachael; Jolin, Hina A; Huebner, Dirk; Radford, John; Luminari, Stefano
Link alla scheda completa:
Pubblicato in: